Assessment of pharmacokinetics and tolerability following single‐dose administration of molnupiravir in participants with hepatic or renal impairment

Assessment of pharmacokinetics and tolerability following single‐dose administration of molnupiravir in participants with hepatic or renal impairment

Abstract Individuals with chronic liver or kidney disease are at increased risk of severe COVID‐19. Molnupiravir is an orally administered antiviral authorized for the treatment of mild‐to‐moderate COVID‐19 in adults at risk of progression to severe disease. Two nonrandomized, open‐label, single‐dos...

Full description

Saved in:
Bibliographic Details
Main Authors: Kelly E. Duncan, Russ P. Carstens, Kristin L. Butterfield, Yoon Jin, Laura R. Inbody, Andrea K. Schaeffer, Catherine Z. Matthews, Tian Zhao, Shruti Patel, Brian M. Maas, Mickie H. Cheng, S. Aubrey Stoch
Format: Article
Language:English
Published: Wiley 2024-12-01
Series:Clinical and Translational Science
Online Access:https://doi.org/10.1111/cts.70073
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1111/cts.70073

Similar Items